RxDoctor Payments Data

Harry Lin, MD

Internal Medicine · Metuchen, NJNPI 1538105895

Payments from drug & device makers

$2,539in general payments, 2019–2025

Across 167 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$332
  • Novo Nordisk$305
  • AstraZeneca$238
  • Amgen$235
  • Exact Sciences$157
  • Lilly USA, LLC$156
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,46797%
  • Education$723%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,539 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$205,905
Medicare patients
385
Services billed
2,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate114$104,533
VascepaIcosapent Ethyl183$74,197
ProliaDenosumab43$69,613
XareltoRivaroxaban35$30,552
EliquisApixaban34$29,076
JardianceEmpagliflozin16$18,076
VemlidyTenofovir Alafenamide11$15,945
LinzessLinaclotide22$14,725
Icosapent Ethyl67$13,699
RestasisCyclosporine13$11,572
Cyclosporine37$11,482
Breo ElliptaFluticasone/Vilanterol26$10,165
Restasis MultidoseCyclosporine15$9,752
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$8,839
FarxigaDapagliflozin Propanediol12$7,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$19$111,398126 claims
AmgenProlia$235$69,61343 claims
AbbVieLinzess, Restasis, Restasis Multidose$66$36,04850 claims
Johnson & JohnsonXarelto$54$30,55235 claims
PfizerEliquis$81$29,07634 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta, Shingrix$130$25,97677 claims
Boehringer IngelheimJardiance$64$18,07616 claims
GileadVemlidy$332$15,94511 claims
AstraZenecaFarxiga$238$7,79812 claims
NovartisEntresto$15$7,35111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Metuchen

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →